Emergency Medicine Cardiac Research and Education Group




ACTION Registry
ACTION Registry®–GWTG™ is a national, risk-adjusted, outcomes-based quality improvement program that helps participating facilities measure and improve care for high-risk ACS patients with STEMI and NSTEMI. The result of the collaboration between the two leading national coronary artery disease registries, the NCDR® ACTION Registry® and the American Heart Association (AHA) Get With The GuidelinesSM-CAD Registry, ACTION Registry–GWTG will be the largest, most comprehensive national cardiovascular patient database ever developed by the medical profession.

Combining the strengths of the two programs, ACTION Registry–GWTG will collect a comprehensive set of data elements that provide healthcare professionals and their facilities with the information they need to monitor and improve adherence to the most current, science-based ACC/AHA treatment guidelines. Participation will greatly facilitate quality improvement efforts, optimize clinical care, and improve clinical outcomes for acute coronary syndrome patients.

Visit How To Join to request additional information or to download an enrollment package. Or, visit the ACTION website for more information.



Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assay



N Engl J Med 2009; 361: 858–867, 868–877 View citation

Background: The rapid and reliable diagnosis of acute myocardial infarction is a major unmet clinical need.

Methods: We conducted a multicenter study to examine the diagnostic accuracy of new, sensitive cardiac troponin assays performed on blood samples obtained in the emergency department from 718 consecutive patients who presented with symptoms suggestive of acute myocardial infarction. Cardiac troponin levels were determined in a blinded fashion with the use of four sensitive assays (Abbott–Architect Troponin I, Roche High-Sensitive Troponin T, Roche Troponin I, and Siemens Troponin I Ultra) and a standard assay (Roche Troponin T). The final diagnosis was adjudicated by two independent cardiologists.

Results: Acute myocardial infarction was the adjudicated final diagnosis in 123 patients (17%). The diagnostic accuracy of measurements obtained at presentation, as quantified by the area under the receiver-operating-characteristic curve (AUC), was significantly higher with the four sensitive cardiac troponin assays than with the standard assay (AUC for Abbott–Architect Troponin I, 0.96; 95% confidence interval [CI], 0.94 to 0.98; for Roche High-Sensitive Troponin T, 0.96; 95% CI, 0.94 to 0.98; for Roche Troponin I, 0.95; 95% CI, 0.92 to 0.97; and for Siemens Troponin I Ultra, 0.96; 95% CI, 0.94 to 0.98; vs. AUC for the standard assay, 0.90; 95% CI, 0.86 to 0.94). Among patients who presented within 3 hours after the onset of chest pain, the AUCs were 0.93 (95% CI, 0.88 to 0.99), 0.92 (95% CI, 0.87 to 0.97), 0.92 (95% CI, 0.86 to 0.99), and 0.94 (95% CI, 0.90 to 0.98) for the sensitive assays, respectively, and 0.76 (95% CI, 0.64 to 0.88) for the standard assay. We did not assess the effect of the sensitive troponin assays on clinical management.

Conclusions: The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.





Legal information

EMCREG™ - International
4555 Lake Forest Drive
Suite 650
Cincinnati, Ohio 45242

Fell free to contact us toll-free at 1-866-4EMCREG (436-2734)





Advanced Search

2 September 2010
27 August 2010
18 August 2010
9 August 2010
2 August 2010
27 July 2010
19 July 2010
19 July 2010
21 June 2010
18 June 2010
11 June 2010
8 June 2010
8 June 2010
NEWS ARCHIVES:
©Copyright EMCREG-International™. All rights reserved